95 related articles for article (PubMed ID: 24953030)
1. Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
Bordessa A; Colin-Cassin C; Grillier-Vuissoz I; Kuntz S; Mazerbourg S; Husson G; Vo M; Flament S; Martin H; Chapleur Y; Boisbrun M
Eur J Med Chem; 2014 Aug; 83():129-40. PubMed ID: 24953030
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
Salamone S; Colin C; Grillier-Vuissoz I; Kuntz S; Mazerbourg S; Flament S; Martin H; Richert L; Chapleur Y; Boisbrun M
Eur J Med Chem; 2012 May; 51():206-15. PubMed ID: 22409968
[TBL] [Abstract][Full Text] [Related]
3. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Saha S; Chan DS; Lee CY; Wong W; New LS; Chui WK; Yap CW; Chan EC; Ho HK
Eur J Pharmacol; 2012 Dec; 697(1-3):13-23. PubMed ID: 23041271
[TBL] [Abstract][Full Text] [Related]
5. Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Mazerbourg S; Kuntz S; Grillier-Vuissoz I; Berthe A; Geoffroy M; Flament S; Bordessa A; Boisbrun M
Curr Top Med Chem; 2016; 16(19):2115-24. PubMed ID: 26881718
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Saha S; New LS; Ho HK; Chui WK; Chan EC
Toxicol Lett; 2010 Feb; 192(2):141-9. PubMed ID: 19854250
[TBL] [Abstract][Full Text] [Related]
7. Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes.
Lauer B; Tuschl G; Kling M; Mueller SO
Chem Biol Interact; 2009 Apr; 179(1):17-24. PubMed ID: 19022234
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379
[TBL] [Abstract][Full Text] [Related]
9. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand.
Nonaka M; Tazuma S; Hyogo H; Kanno K; Chayama K
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e198-206. PubMed ID: 17868335
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.
Vansant G; Pezzoli P; Saiz R; Birch A; Duffy C; Ferre F; Monforte J
Int J Toxicol; 2006; 25(2):85-94. PubMed ID: 16597547
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone and 9cis,11trans,13trans-conjugated linolenic acid: comparison of their antiproliferative and apoptosis-inducing effects on different colon cancer cell lines.
Yasui Y; Hosokawa M; Kohno H; Tanaka T; Miyashita K
Chemotherapy; 2006; 52(5):220-5. PubMed ID: 16899971
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis.
Little PJ; Ballinger ML; Survase S; Osman N; Ogru E; Geytenbeek S; Bruemmer D; Nigro J
J Cardiovasc Pharmacol; 2008 Mar; 51(3):274-9. PubMed ID: 18356692
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium.
Fan YH; Chen H; Natarajan A; Guo Y; Harbinski F; Iyasere J; Christ W; Aktas H; Halperin JA
Bioorg Med Chem Lett; 2004 May; 14(10):2547-50. PubMed ID: 15109648
[TBL] [Abstract][Full Text] [Related]
15. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells.
Yamamoto Y; Yamazaki H; Ikeda T; Watanabe T; Iwabuchi H; Nakajima M; Yokoi T
Drug Metab Dispos; 2002 Feb; 30(2):155-60. PubMed ID: 11792684
[TBL] [Abstract][Full Text] [Related]
16. Development of small-molecule cyclin D1-ablative agents.
Huang JW; Shiau CW; Yang J; Wang DS; Chiu HC; Chen CY; Chen CS
J Med Chem; 2006 Jul; 49(15):4684-9. PubMed ID: 16854074
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
[TBL] [Abstract][Full Text] [Related]
18. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes.
Saha S; New LS; Ho HK; Chui WK; Chan EC
Toxicol Lett; 2010 Jun; 195(2-3):135-41. PubMed ID: 20307632
[TBL] [Abstract][Full Text] [Related]
19. Species-specific toxicity of troglitazone on rats and human by gel entrapped hepatocytes.
Shen C; Meng Q; Zhang G
Toxicol Appl Pharmacol; 2012 Jan; 258(1):19-25. PubMed ID: 22085495
[TBL] [Abstract][Full Text] [Related]
20. Toxic effect of troglitazone on cultured rat hepatocytes.
Toyoda Y; Tsuchida A; Iwami E; Miwa I
Life Sci; 2001 Mar; 68(16):1867-76. PubMed ID: 11292064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
